Generic Monoferric Availability
Last updated on May 7, 2025.
Monoferric is a brand name of ferric derisomaltose, approved by the FDA in the following formulation(s):
MONOFERRIC (ferric derisomaltose - solution;intravenous)
-
Manufacturer: PHARMACOSMOS
Approval date: January 16, 2020
Strength(s): 1GM/10ML (100MG/ML) [RLD], 100MG/ML (100MG/ML) (discontinued) [RLD], 500MG/5ML (100MG/ML) (discontinued) [RLD]
Is there a generic version of Monoferric available?
No. There is currently no therapeutically equivalent version of Monoferric available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Monoferric. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Stable iron oligosaccharide compound
Patent 10,414,831
Issued: September 17, 2019
Inventor(s): Andreasen Hans
Assignee(s): PHARMACOSMOS HOLDING A/SThe invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimes saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
Patent expiration dates:
- March 25, 2029✓✓
- March 25, 2029
-
Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant
Patent 11,633,489
Issued: April 25, 2023
Inventor(s): Thomsen; Lars Lykke et al.
Assignee(s): PHARMACOSMOS HOLDING A/S (Holbaek, DK)Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.
Patent expiration dates:
- June 22, 2036✓
- June 22, 2036
-
Stable iron oligosaccharide compound
Patent 11,851,504
Issued: December 26, 2023
Inventor(s): Andreasen; Hans
Assignee(s): PHARMACOSMOS HOLDING A/S (Holbaek, DK)The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
Patent expiration dates:
- March 25, 2029✓✓
- March 25, 2029
-
Stable iron oligosaccharide compound
Patent 12,030,962
Issued: July 9, 2024
Inventor(s): Andreasen; Hans
Assignee(s): PHARMACOSMOS HOLDING A/S (Holbaek, DK)The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosacharride in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
Patent expiration dates:
- March 25, 2029✓✓
- March 25, 2029
-
Stable iron oligosaccharide compound
Patent 8,815,301
Issued: August 26, 2014
Inventor(s): Andreasen Hans
Assignee(s): Pharmacosmos Holding A/SThe invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
Patent expiration dates:
- August 14, 2029✓✓✓
- August 14, 2029
More about Monoferric (ferric derisomaltose)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: iron products
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
